Current prospects for interferon-free treatment of hepatitis C in 2012

被引：59

作者：

Stedman, Catherine A. M. ^{[1
]}

机构：

[1] Christchurch Hosp, Christchurch 8140, New Zealand

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷 / 01期

关键词：

direct-acting antivirals; hepatitis C; interferon-free; 1B-INFECTED NULL RESPONDERS; TREATMENT-NAIVE PATIENTS; GENOTYPE; INFECTION; PROTEASE INHIBITOR; VIRUS-INFECTION; PLUS RIBAVIRIN; FREE REGIMEN; GENOTYPE-1-INFECTED SUBJECTS; NONNUCLEOSIDE POLYMERASE; PEGINTERFERON ALPHA-2A;

D O I：

10.1111/jgh.12028

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit hepatitis C virus replication to be licensed for use in conjunction with pegylated interferon and ribavirin. Numerous other DAAs are in clinical development, and phases 2 and 3 trials are evaluating interferon-free combination DAA therapy. Interferon-free sustained virologic responses have now been achieved with combinations of asunaprevir and daclatasvir; sofosbuvir and ribavirin; sofosbuvir and daclatasvir; faldaprevir and BI207127; ABT-450, ritonovir and ABT-333; ABT-450, ritonovir and ABT-072; miracitabine, danoprevir and ritonavir; and alisporivir and ribavirin. Some drugs are genotype-specific in their activity, whereas others are pan-genotypic, and differential responses for the genotype 1 subtypes 1a and 1b have emerged with many DAA combinations. Viral breakthrough and resistance are important considerations for future trial design. The prospect of interferon-free combination DAA therapy for hepatitis C virus is now finally becoming a reality.

引用

页码：38 / 45

页数：8

共 38 条

[1] Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders [J].

Chayama, Kazuaki ;

Takahashi, Shoichi ;

Toyota, Joji ;

Karino, Yoshiyasu ;

Ikeda, Kenji ;

Ishikawa, Hiroki ;

Watanabe, Hideaki ;

McPhee, Fiona ;

Hughes, Eric ;

Kumada, Hiromitsu .

HEPATOLOGY, 2012, 55 (03) :742-748

[2] Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C [J].

Chu, Tom W. ;

Kulkarni, Rohit ;

Gane, Edward J. ;

Roberts, Stuart K. ;

Stedman, Catherine ;

Angus, Peter W. ;

Ritchie, Brett ;

Lu, Xiao-Yu ;

Ipe, David ;

Lopatin, Uri ;

Germer, Soren ;

Iglesias, Victor A. ;

Elston, Robert ;

Smith, Patrick F. ;

Shulman, Nancy S. .

GASTROENTEROLOGY, 2012, 142 (04) :790-795

[3] VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS [J].

Di Bisceglie, A. M. ;

Nelson, D. R. ;

Gane, E. ;

Alves, K. ;

Koziel, M. J. ;

De Souza, C. ;

Kieffer, T. L. ;

George, S. ;

Kauffman, R. S. ;

Jacobson, I. M. ;

Sulkowski, M. S. .

JOURNAL OF HEPATOLOGY, 2011, 54 :S540-S540

[4] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[5]

Gane E, 2012, J HEPATOL, V56, pA1412

[6] Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial [J].

Gane, Edward J. ;

Roberts, Stuart K. ;

Stedman, Catherine A. M. ;

Angus, Peter W. ;

Ritchie, Brett ;

Elston, Rob ;

Ipe, David ;

Morcos, Peter N. ;

Baher, Linda ;

Najera, Isabel ;

Chu, Tom ;

Lopatin, Uri ;

Berrey, M. Michelle ;

Bradford, William ;

Laughlin, Mark ;

Shulman, Nancy S. ;

Smith, Patrick F. .

LANCET, 2010, 376 (9751) :1467-1475

[7]

Gane EJ, 2012, N ENGL J ME IN PRESS

[8] Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].

Ge, Dongliang ;

Fellay, Jacques ;

Thompson, Alexander J. ;

Simon, Jason S. ;

Shianna, Kevin V. ;

Urban, Thomas J. ;

Heinzen, Erin L. ;

Qiu, Ping ;

Bertelsen, Arthur H. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

McHutchison, John G. ;

Goldstein, David B. .

NATURE, 2009, 461 (7262) :399-401

[9]

Hezode C, 2012, J HEPATOL, V56, pA8

[10] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

← 1 2 3 4 →